ACIST Medical Systems Announces Approval and Launch of Next-Generation FFR System
ACIST Launches Direct Sales of its CVi Contrast Delivery System in Japan
Impact of Post-Intervention Fractional Flow Reserve Measurement on Acute PCI Outcomes Investigated in Large Independent Registry
Head-to-Head Study Validates Consistent Performance of Microcatheter FFR
ACIST Japan Launches ACIST HDi® High Definition IVUS
Enrollment Complete for ACIST-FFR Multi-Center Study
ACIST Inc., Announces ACIST Japan Inc., Will Take Over Distribution of CVi Contrast Delivery Injector in Japan
View press release
Junichi Osawa appointed to lead ACIST’s injector business in Japan together with valued partner DVx Inc.
ACIST Japan facility opens.
ACIST Japan, K.K is established.
Launches the ACIST CVI® Contrast Delivery System, combining the capabilities of the CMS and Voyager® into one integrated system.
One thousand ACIST systems are being used in more than 30 countries worldwide.
ACIST partners with DVx Inc. to sell ACIST products in Japan.
Renamed ACIST (Automated Contrast Injection System Technology) Medical Systems to better reflect the company’s focus.
Licenses five-year marketing rights to New Jersey-based Bracco Diagnostics Inc., which has a nationwide distribution network.
Receives FDA clearance to market the CL100H system, the first injection system for diagnostic and interventional cardiology.
Incorporates as Invasatec.
Company is founded by Dr. Robert (Bob) F. Wilson, Professor of Medicine and Director of the Interventional Cardiology Program at the University of Minnesota.